NCT00001133View on ClinicalTrials.gov

Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

August 31, 2006

Conditions

HIV Infections

Interventions

DRUG

Indinavir sulfate

DRUG

Ritonavir

Trial Locations (7)

10016

NY Univ. HIV/AIDS CRS, New York

15213

Pitt CRS, Pittsburgh

21287

Johns Hopkins Adult AIDS CRS, Baltimore

35294

Alabama Therapeutics CRS, Birmingham

94110

Ucsf Aids Crs, San Francisco

452670405

Univ. of Cincinnati CRS, Cincinnati

900331079

USC CRS, Los Angeles

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001133 - Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir | Biotech Hunter | Biotech Hunter